Author:
Chen Wang-Qing,Shu Yan,Li Qing,Xu Lin-Yong,Roederer Mary W.,Fan Lan,Wu Lan-Xiang,He Fa-Zhong,Luo Jian-Quan,Tan Zhi-Rong,He Yi-Jing,Zhou Hong-Hao,Chen Xiang,Zhang Wei
Publisher
Public Library of Science (PLoS)
Reference38 articles.
1. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, et al.. (1993) Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med. 328, 914–21.
2. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, et al.. (2008) Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 358, 1547–59.
3. Stangier J, Su CA, Schondorfer G, Roth W (2000) Pharmacokinetics and safety of intravenous and oral telmisartan 20 mg and 120 mg in subjects with hepatic impairment compared with healthy volunteers. J Clin Pharmacol. 40, 1355–64.
4. Tatami S, Sarashina A, Yamamura N, Igarashi T, Tanigawara Y (2003) Population pharmacokinetics of an angiotensin II receptor antagonist, telmisartan, in healthy volunteers and hypertensive patients. Drug Metab Pharmacokinet. 18, 203–11.
5. Zhang P, Zhang Y, Chen X, Li R, Yin J, et al.. (2006) Pharmacokinetics of telmisartan in healthy Chinese subjects after oral administration of two dosage levels. Arzneimittelforschung. 56, 569–73.
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献